Cellipont Bioservices, a leading Contract Development and Manufacturing Organization (CDMO) specializing in cell therapies, has expanded its partnership with CellVax Therapeutics Inc. to advance the development of personalized immunotherapy for gastrointestinal cancers. The collaboration includes manufacturing support for FK-GI101, an autologous cell-based immunotherapy targeting gastric, pancreatic, and colon cancer. FK-GI101 utilizes CellVax’s proprietary platform, which modifies a patient’s own tumor cells to enhance immune system visibility and stimulate a personalized immune response against residual or recurring tumor cells.
This innovative approach aims to address urgent unmet medical needs in gastrointestinal cancers. Darren Head, CEO of Cellipont Bioservices, expressed pride in deepening the collaboration with CellVax and highlighted the transformative potential of FK-GI101. Fernando Kreutz, CEO of CellVax Therapeutics, emphasized the importance of scaling their personalized immunotherapy platform with the support of Cellipont’s manufacturing infrastructure and expertise. CellVax Therapeutics is a clinical-stage company focused on individualized cell-based immunotherapies, aiming to improve outcomes in solid tumors. For more information, visit www.cellvx.com.
Read more from uk.finance.yahoo.com